Genetic Engineering & Biotechnology News: Heart Disease May Be Treatable with HDAC6 Inhibitor, Preclinical Data Suggests

Jul 11, 2022
PDF Version

Tenaya’s preclinical study for dilated cardiomyopathy, published in July 2022, is detailed in this article from GEN. The study identified the HDAC6 inhibitor as a target for the potential treatment of DCM.

Read More

RSS Feeds
Email Alerts
Contact IR
Print